Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $865
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice TargetHot
Piper Sandler analyst Biren Amin maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $854 to $865.
Piper Sandler analyst Biren Amin maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $854 to $865.